U.S. Stock News

James River Group Holdings (JRVR) posted a continued loss, with the company’s losses increasing at an average rate of 2.3% per year over the past five years. Looking ahead, analysts expect earnings to rebound sharply and are forecasting annual growth of 88.79% with a return to profitability within three years. With relative value compared to peers and the prospect of rapid earnings improvement, investors may see reasons for optimism despite a challenging recent track record. See our full...

Ever wondered if Public Storage stock is a bargain right now, or if there's a better place to put your money? You're not alone, and it's exactly the question we're diving into today. The shares have been on a bit of a rollercoaster lately, with a 7.4% drop in the last week and 15.7% over the past year, but they're still up nearly 46% over the last five years. Recent headlines have focused on shifting investor sentiment and larger trends in the real estate sector, with industry news...

ZoomInfo Technologies (GTM) posted a net profit margin of 8.4%, a substantial jump from last year’s 0.7%, even after absorbing a hefty one-off loss of $101.6 million over the last twelve months through September 30, 2025. Earnings are projected to grow at 19.6% per year, outpacing the US market's expected 16% annual growth, while revenue is set to rise at a slower 3.7% annually versus the market average of 10.5%. With sustained profitability gains and a discounted cash flow suggesting shares...

Super Group (SGHC) posted a striking surge in net profit margins, coming in at 9.8% compared to just 0.3% last year. This improvement was fueled by an extraordinary 4,994.9% earnings growth over the same period. Looking ahead, the company’s earnings are expected to grow 32.2% per year, far outpacing the broader US market’s forecast of 16% per year. Revenue is projected to rise by 9.2% annually, just below the US average of 10.5%. With these numbers, investors are seeing a notable turnaround...

Exact Sciences (EXAS) remains unprofitable, with losses increasing at an average pace of 1.5% per year over the past five years. Supported by a revenue growth forecast of 10.4% per year and projected earnings acceleration of 89.51% per year, the company is expected to reach profitability within three years, a faster turnaround than the broader market. Investors are likely to focus on the stock’s strong relative and absolute value metrics, as well as anticipated profit and revenue gains, even...

Armada Hoffler Properties (AHH) recently reported figures that point to a turning point, with revenue expected to decline by 10.1% per year over the next three years, even as earnings are forecast to grow at a brisk 21.8% annually. The company has just turned profitable and logged a major one-off gain of $27.2 million in the last 12 months. Despite a five-year track record of earnings declining by 16.1% per year, management now foresees a sharp rebound in bottom-line performance. This sets up...

Voyager Technologies (VOYG) remains unprofitable, with no established year-on-year earnings trend so far, as the company has been publicly traded for less than three years. Revenue is forecast to surge 51.5% per year, far outpacing the US market average of 10.5%. However, net margins remain negative and the Price-To-Sales Ratio sits at a steep 10.3x, well above industry and peer benchmarks. With investors focused on whether overhead and costs are being effectively controlled, the company’s...

Addus HomeCare (ADUS) delivered earnings growth of 16.3% over the past year, with a robust five-year compound annual growth rate for earnings of 19.4%. Earnings are forecast to keep climbing at 16.4% per year, outpacing the broader US market average forecast, while net profit margins held steady at 6.4% compared to 6.5% a year ago. Although revenue growth is set to lag the wider market at 7.8% annually, the company’s consistent track record of profitability and favorable valuation relative to...

Syndax Pharmaceuticals (SNDX) remains unprofitable as net losses have widened at 41.3% per year over the past five years. Net profit margins have stayed negative with no track record of high-quality earnings. Looking forward, revenue is forecast to climb 40.4% annually, outpacing the US market. Earnings are projected to surge 72.8% per year with profitability expected within three years. The share price has settled at $15.35, notably below its estimated fair value of $214.76. The company...

Vornado Realty Trust (VNO) has turned profitable, posting a robust 46.1% per year earnings growth rate over the last five years, but recent results were boosted by a one-off gain of $827.3 million. Although net profit margins have moved into positive territory, forecasts now call for earnings to drop sharply by 83.8% per year over the coming three years. Revenue is projected to rise at a slower 3.3% per year, which is behind the broader US market’s 10.5% per year expectation. With profits...

Kontoor Brands (KTB) is forecasting impressive earnings growth of 20.9% per year, outpacing the US market average of 16%. Current net profit margins have compressed to 7.7% from last year's 9.7%, and over the past five years, the company has averaged 12.4% annual earnings growth, despite recent negative momentum. With top-line growth likely but near-term margin pressure evident, investors are weighing this strong outlook against recent softness in profitability. See our full analysis for...

Thinking about Oshkosh stock and whether it’s great value right now? You’re not alone, and the numbers are worth a closer look. After climbing 28.7% year-to-date, Oshkosh’s price has pulled back noticeably with a 12.4% drop over the past week and an 8.4% decline in 30 days, sparking some big questions about what is driving investor sentiment. These moves come amid news highlighting Oshkosh’s contracts in specialty vehicles and changing defense sector demand. Market commentary around shifts...

Ichor Holdings (ICHR) reported continued unprofitability, with losses worsening at an annual rate of 50.5% over the past five years. Yet, with EPS forecast to rise 77.73% per year and a path to profitability expected within three years, investors eye deep value in the company’s notably low 0.6x Price-To-Sales Ratio, especially when compared to US semiconductor peers trading around 5x sales. The setup is clear: the company’s robust projected profit growth competes with lower-than-market...

Harmonic (HLIT) reported a net profit margin of 7.8%, down from 13.6% the previous year, highlighting a decline in profitability. Despite this margin pressure, the company’s revenue is forecast to grow at 8.6% annually, which is slower than the broader US market’s 10.5%. While earnings growth over the last year was negative, Harmonic has posted an impressive 48.6% annualized earnings growth rate over the past five years, demonstrating substantial long-term gains. Looking forward, earnings are...

Fabrinet (FN) reported annual earnings growth of 13.9%, contributing to an impressive five-year average earnings growth rate of 20.1%. Earnings are forecast to rise at 18.66% per year, while revenue is projected to increase 17.4% annually. Both figures are expected to outpace the broader US market’s growth expectations. However, net profit margins narrowed to 9.8% from 10.3% last year, signaling some margin compression worth noting for investors. See our full analysis for Fabrinet. The next...

Wondering whether KBR is trading at a bargain or if it is looking pricey right now? Let’s break down the numbers and see what’s going on beneath the surface. KBR’s stock has had a rough ride this year, dropping 26.7% year to date and down 36.9% over the past 12 months. Looking back five years, however, it is still up nearly 70%. These recent moves follow several high-profile contract wins and industry updates, which have added both excitement and uncertainty. Market sentiment has shifted as...

If you’ve ever wondered whether Upwork is fairly priced, undervalued, or too expensive to buy right now, you’re not alone. It’s the question every savvy investor should ask before hitting “buy.” Upwork shares have gained 23.0% over the past year and are up 7.9% year-to-date, so there’s definitely momentum and changing sentiment to consider. After a wave of headlines spotlighting Upwork’s expanding partnerships with enterprise clients and increased interest in flexible remote work, the...

Wondering if Essent Group is currently a smart buy? You are not alone, especially with so much chatter about its valuation and long-term potential. The stock has climbed 17.8% over the past year and is up 13.6% year-to-date. This signals changing market sentiment and perhaps renewed optimism among investors. Recent headlines have highlighted Essent Group's strategic expansion efforts and strong operating performance. These factors have fueled both investor curiosity and notable price gains...

Ever wondered if IMAX stock is actually a bargain right now or if you might be catching it after the main show? Let's break down what's really behind the numbers to help you decide if it's worth a spot in your portfolio. IMAX has posted an impressive 29.5% year-to-date return and is up 34.1% over the last year, even with minor dips of -0.7% in the past week and -3.5% over the past month. Part of this momentum has been fueled by renewed excitement around blockbuster releases and growing...

Ever wondered if Alight could be a hidden gem or is already priced to perfection? If you’re on the hunt for value, you might be surprised by what the numbers reveal. It's been a rollercoaster for Alight’s shareholders. They have seen the stock drop 12.3% in the last week and a staggering 60.0% since the start of the year, signaling a big shift in how the market values the business. Recently, Alight made headlines by entering new partnerships that aim to strengthen its position in the...

CytomX Therapeutics announced it will present initial translational data from its ongoing Phase 1 study of CX-801 in advanced melanoma at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, MD. This upcoming clinical update provides stakeholders with a key opportunity to assess the potential of CytomX's immunotherapy pipeline, possibly shaping future expectations around its development progress and clinical...

Cabaletta Bio (CABA) gained traction after sharing positive updates on its lead therapy, rese-cel, at the American College of Rheumatology Convergence 2025. The company outlined clinical progress in autoimmune disease trials for myositis, systemic sclerosis and lupus. See our latest analysis for Cabaletta Bio. The buzz from Cabaletta Bio’s clinical updates comes after a remarkable stretch for the stock, with a 23% gain in the past month and a significant 94% share price return over 90 days...

BioNTech (BNTX) remains unprofitable, with net losses increasing at an annual rate of 22.1% over the past five years. While revenue is projected to grow just 1.7% per year, which is much slower than the broader US market's 10.5% rate, the company is expected to stay in the red for at least the next three years. Investors may take note of BioNTech trading below analyst price targets, but persistent weak margins and muted growth expectations continue to cloud the overall outlook. See our full...

If you have ever wondered whether Sonos might actually be a value pick hiding in plain sight, you are not alone. Let's get right to the heart of what the numbers and recent headlines reveal. After a 24.7% gain over the last year and a 14.0% lift year-to-date, Sonos stock has certainly caught some fresh attention. However, short-term dips of -4.6% this week and -1.2% over the past month signal there is still some volatility to watch. Recent news has included Sonos’ ongoing efforts to expand...